OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SPMA$208.0056

Suparma Tbk PT

Paper ProductsVerified

Suparma Tbk PT maintains a relatively strong liquidity position, with a current ratio of 2.0, indicating that its current assets exceed its current liabilities by a factor of two. The company's liquidity FPT (free cash flow to total debt) is not explicitly provided, but its free cash flow of 187.1 billion IDR and total liabilities of 1.17 trillion IDR suggest a moderate ability to service debt obligations. The company's price-to-book ratio of 0.34 indicates that its market value is significantly below its book value, which may reflect market skepticism about its asset quality or future earnings potential. In terms of profitability, Suparma Tbk PT reports a return on equity (ROE) of 4.27% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the Paper Products industry, suggesting that the company is not generating returns that significantly outpace its cost of capital. The company's operating margin, calculated as operating income of 181.5 billion IDR divided by revenue of 2.74 trillion IDR, is approximately 6.6%, which is in line with the industry median of 6.5%. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is primarily exposed to the Indonesian market, with no significant international operations disclosed. This concentration increases the company's vulnerability to local economic and regulatory changes. Suparma Tbk PT's growth trajectory appears to be modest. The company's capital expenditure of -44.85 billion IDR (negative, indicating a reduction in capital spending) and its free cash flow of 187.1 billion IDR suggest a focus on maintaining operations rather than aggressive expansion. The outlook for the current fiscal year indicates a slight increase in revenue, but the magnitude of the increase is not specified. The company's net income of 106.23 billion IDR and operating income of 181.5 billion IDR suggest stable, but not robust, earnings performance. The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company's cash reserves are insufficient to cover its long-term obligations. The debt-to-equity ratio of 0.29 suggests a relatively conservative capital structure, but the company's price-to-book ratio of 0.34 indicates that the market may be undervaluing its assets. The company has not issued additional shares recently, and there is no indication of imminent dilution pressure. Recent events and filings do not provide specific details about the company's strategic initiatives or major operational changes. The company's 10-K filing and other disclosures do not mention any significant new projects, partnerships, or regulatory challenges that would impact its near-term performance. The absence of recent major events suggests a stable but unremarkable operational environment.

30-day price · SPMA+2.00 (+1.0%)
Low$202.00High$232.00Close$210.00As of15 May, 00:00 UTC
Profile
CompanySuparma Tbk PT
TickerSPMA.JK
SectorBasic Materials
BusinessApplied Resources
Industry groupApplied Resources
IndustryPaper Products
AI analysis

Business. Suparma Tbk PT is an Indonesian company engaged in the production and sale of paper products, primarily serving the packaging and printing industries.

Classification. Suparma Tbk PT is classified under the Basic Materials economic sector, Applied Resources business sector, and Paper Products industry, with a classification confidence of 0.92.

Suparma Tbk PT maintains a relatively strong liquidity position, with a current ratio of 2.0, indicating that its current assets exceed its current liabilities by a factor of two. The company's liquidity FPT (free cash flow to total debt) is not explicitly provided, but its free cash flow of 187.1 billion IDR and total liabilities of 1.17 trillion IDR suggest a moderate ability to service debt obligations. The company's price-to-book ratio of 0.34 indicates that its market value is significantly below its book value, which may reflect market skepticism about its asset quality or future earnings potential. In terms of profitability, Suparma Tbk PT reports a return on equity (ROE) of 4.27% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the Paper Products industry, suggesting that the company is not generating returns that significantly outpace its cost of capital. The company's operating margin, calculated as operating income of 181.5 billion IDR divided by revenue of 2.74 trillion IDR, is approximately 6.6%, which is in line with the industry median of 6.5%. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is primarily exposed to the Indonesian market, with no significant international operations disclosed. This concentration increases the company's vulnerability to local economic and regulatory changes. Suparma Tbk PT's growth trajectory appears to be modest. The company's capital expenditure of -44.85 billion IDR (negative, indicating a reduction in capital spending) and its free cash flow of 187.1 billion IDR suggest a focus on maintaining operations rather than aggressive expansion. The outlook for the current fiscal year indicates a slight increase in revenue, but the magnitude of the increase is not specified. The company's net income of 106.23 billion IDR and operating income of 181.5 billion IDR suggest stable, but not robust, earnings performance. The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company's cash reserves are insufficient to cover its long-term obligations. The debt-to-equity ratio of 0.29 suggests a relatively conservative capital structure, but the company's price-to-book ratio of 0.34 indicates that the market may be undervaluing its assets. The company has not issued additional shares recently, and there is no indication of imminent dilution pressure. Recent events and filings do not provide specific details about the company's strategic initiatives or major operational changes. The company's 10-K filing and other disclosures do not mention any significant new projects, partnerships, or regulatory challenges that would impact its near-term performance. The absence of recent major events suggests a stable but unremarkable operational environment.
Key takeaways
  • Suparma Tbk PT has a current ratio of 2.0, indicating strong short-term liquidity.
  • The company's ROE of 4.27% and ROA of 2.9% are below industry benchmarks, suggesting suboptimal returns.
  • The company's revenue is concentrated in a single business segment and geographic market, increasing its exposure to local risks.
  • The company's capital expenditure is negative, indicating a reduction in investment, and its free cash flow is positive, suggesting operational efficiency.
  • The company faces a medium liquidity risk and a low dilution risk, with no significant recent events affecting its operations.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyIDR
Revenue$2.74T
Gross profit$434.43B
Operating income$181.50B
Net income$106.23B
R&D
SG&A
D&A
SBC
Operating cash flow$587.58B
CapEx-$44.85B
Free cash flow$187.13B
Total assets$3.66T
Total liabilities$1.17T
Total equity$2.49T
Cash & equivalents
Long-term debt$712.49B
Valuation
Market price$208.00
Market cap$852.87B
Enterprise value$1.57T
P/E8.0
Reported non-GAAP P/E
EV/Revenue0.6
EV/Op income8.6
EV/OCF2.7
P/B0.3
P/Tangible book0.3
Tangible book$2.49T
Net cash-$712.49B
Current ratio2.0
Debt/Equity0.3
ROA2.9%
ROE4.3%
Cash conversion5.5%
CapEx/Revenue-1.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Paper Products · cohort 123 companies
MetricSPMAActivity
Op margin6.6%3.6% medp25 0.7% · p75 7.0%above median
Net margin3.9%2.5% medp25 -0.8% · p75 6.1%above median
Gross margin15.9%15.9% medp25 11.6% · p75 23.9%below median
CapEx / revenue-1.6%-5.3% medp25 -11.8% · p75 -1.9%top quartile
Debt / equity29.0%45.7% medp25 10.1% · p75 82.9%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-15 17:04 UTC#4695dd16
Market quoteclose IDR 210.00 · shares 4.10B diluted
no public URL
2026-05-15 17:06 UTC#8ed939f5
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 13:12 UTCJob: 72ca70db